NewsAI-assisted

Union Cabinet Approves Major Boost For Biotech Manufacturing

BioE3 policy boosts India's biomanufacturing with sustainable innovation, aiming for net-zero by 2070

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Aug 27, 2024Updated Jun 26, 2025 · 2 min read
Share
Union Cabinet Approves Major Boost For Biotech Manufacturing
Union Minister Ashwini Vaishnaw addressing the media on Cabinet Decision at National Media Center on Saturday. | Photo Credit: Sushil Kumar Verma
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

The Union Cabinet has greenlit the BioE3 policy, marking a significant leap forward in India’s biomanufacturing sector. This policy aims to foster sustainable and circular practices, driving innovation and supporting green growth in the country. BioE3, which stands for Biotechnology for Economy, Environment, and Employment, is a key component of India’s strategy to achieve net zero emissions by 2070. With a budget of over Rs 10,579 crore allocated from 2021-22 to 2025-26, the policy will be instrumental in advancing technology, entrepreneurship, and commercialization. 

This will be achieved through the creation of biomanufacturing hubs, Bio-AI centers, and biofoundries. The policy places a strong emphasis on high-value bio-based products, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture, and cutting-edge research in marine and space sectors.

Additionally, the Cabinet has sanctioned the continuation of three existing schemes under a unified central scheme called ‘Vigyan Dhara’. This consolidation will enhance institutional and human capacity building, R&D, and technology deployment, ensuring more efficient use of funds and better coordination. The R&D initiatives will be aligned with the Anusandhan National Research Foundation (ANRF), adhering to global standards and addressing national priorities. This project is expected to generate employment, expand India’s skilled workforce, and tackle critical issues like climate change, food security, and human health.

 

TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

More from Pharma News

All stories →